Cyfuse Biomedical K.K.
4892・Growth Market・Pharmaceuticals
Governance
Company with a Board of Corporate Auditors. Composed of 5 directors (including 2 outside directors) and 3 corporate auditors (all outside). A Compliance and Risk Committee is held quarterly; no Nomination Committee or Compensation Committee has been established. The Board of Directors met 15 times during the fiscal year under review (all members attended).
Risk Management
Based on information gathered by each department, risk information is shared through the Management Committee and the Compliance and Risk Committee (held quarterly), with efforts made toward early detection and prevention. A system has been established to mitigate risk by leveraging collaboration with external experts such as attorneys and certified public accountants, as well as audits by the Audit & Supervisory Board Members and internal audits.
Shareholder Returns
No dividends have been paid since establishment. Retained earnings carried forward are negative, and the company plans to prioritize upfront investment in R&D while focusing on retaining internal earnings for the time being. It states that it will consider realizing dividends at an early stage while taking into account business performance and financial condition.
Dividend Policy
The company has not paid dividends since its establishment, and as retained earnings carried forward remain negative at the end of the current fiscal year, no dividend will be paid. It is expected to take several years or more before the regenerative medicine pipeline development contributes to earnings, and for the time being the company intends to retain earnings internally and allocate them to R&D funding. If dividends are paid, the basic policy is a single year-end dividend, and provisions for interim dividends are also stipulated in the Articles of Incorporation.
ESG
Under the mission of "creating hope from cells," the company positions the resolution of social challenges through the popularization of regenerative medicine and alternative methods to animal testing as the core of its business. In terms of human capital, it promotes work-life balance and encourages men to take childcare leave through its proprietary "Mahoroba Project," continues its stock option program, and conducts educational activities for students (Cycamp). In its IP strategy, the company received the Minister of Economy, Trade and Industry Award for Contribution to Intellectual Property in FY2024 (Reiwa 6). It has not set quantitative ESG indicators or targets at this time, adopting a policy that emphasizes practical implementation.
Last updated: March 27, 2026